PharmaCyte Biotech Makes $7M Investment In MyMD Pharmaceuticals; Investment In Life Sciences Solidifies Previously Announced Strategy To Utilize Significant Cash Position To Create Additional Stockholder Value
PharmaCyte Biotech Makes $7M Investment In MyMD Pharmaceuticals; Investment In Life Sciences Solidifies Previously Announced Strategy To Utilize Significant Cash Position To Create Additional Stockholder Value
Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value
對生命科學的第二項外部投資鞏固了先前宣佈的利用大量現金狀況爲股東創造額外價值的戰略
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD") a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions. MyMD has announced positive data for a 40-patient Phase 2 clinical trial for its lead product, MYMD-1 in sarcopenia, and is moving its clinical program forward in consultation with the U.S. Food and Drug Administration (FDA). PharmaCyte's investment in externally developed technology solidifies its strategy to prudently apply its approximately $65 million (as of March 31, 2024) cash position.
Pharmacyte Biotech, Inc.（納斯達克股票代碼：PMCB）（“PharmacYTE” 或 “公司”）今天宣佈向MyMD Pharmicals, Inc.（納斯達克股票代碼：MYMD）（“myMD”）投資700萬美元，這是一家臨床階段的生物製藥公司，致力於開發針對年齡相關疾病、自身免疫和炎症性疾病的新療法。MyMD 公佈了其主要產品 MYMD-1 治療肌肉減少症的 40 名患者 2 期臨床試驗的陽性數據，並正在與美國食品藥品監督管理局 (FDA) 磋商，推進其臨床項目。PharmacYTE對外部開發技術的投資鞏固了其謹慎運用其約6500萬美元（截至2024年3月31日）現金狀況的戰略。